Mirabegron Clinical Guidelines

Introduction to Mirabegron Therapy

The American Urological Association recommends mirabegron 25 mg as a particularly effective and safe dose in older patients (≥65 years) with multiple comorbidities 1, 2

Combination therapy with mirabegron 50 mg and solifenacin 5 mg provides superior efficacy compared to either drug alone, with statistically significant reductions in urinary incontinence episodes, urgency episodes, and nocturia 3, 1
The effect sizes for combination therapy (0.65-0.95) exceed those of monotherapy (0.36-0.56 for various measures), according to the European Association of Urology 3

The American Heart Association recommends monitoring blood pressure periodically, especially in hypertensive patients and during initial treatment, due to the potential risk of hypertension 2
Regular re-evaluation of symptoms and post-void residual volume is necessary for men with lower urinary tract symptoms, as suggested by the American Urological Association 2

The European Urology guidelines recommend monitoring blood pressure periodically in elderly patients taking mirabegron, especially during initial treatment and in patients with hypertension, as mirabegron can cause dose-dependent blood pressure increases 4
Mirabegron is contraindicated in severe uncontrolled hypertension, according to the European Urology guidelines 4
The most frequent adverse events associated with mirabegron are hypertension, urinary tract infections, headache, and nasopharyngitis, as reported in the European Urology journal 4

The European Urology journal reports that mirabegron does not cause significant anticholinergic effects, such as dry mouth, constipation, and cognitive impairment, making it a suitable option for elderly patients 4